Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s…
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers The…